Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs

Expert Opinion on Drug Safety

Volumn 5, Issue 1, 2006, Pages 83-94

  Maillard, Marc ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cardiovascular; COX 2 inhibitor; Hypertension; Ibuprofen; Myocardial infarction; Naproxen; Nonsteroidal anti inflammatory drug (NSAID)

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIURETIC AGENT; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; PLACEBO; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN D2; PROSTAGLANDIN E2; ROFECOXIB; SULINDAC; THROMBOXANE A2;

ACUTE KIDNEY FAILURE; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; META ANALYSIS; MORTALITY; NONHUMAN; OBESITY; OSTEOARTHRITIS; PERIPHERAL EDEMA; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SMOKING; SODIUM RETENTION; STROKE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PLATELETS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; HUMANS; KIDNEY; RISK FACTORS;

EID: 30344461256     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.1.83     Document Type: Review

References (71)

1. GREEN GA: Understanding NSAIDs: from aspirin to COX-2. Clin. Cornerstone (2001) 3:50-60.
2. AMERICAN COLLEGE OF RHEUMATOLOGY: Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. (2000) 43:1905-1915.
3. FITZGERALD GA, PATRONO C: The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. (2001) 345:433-442.
4. RUBIN BR, BURTON R, NAVARRA S et al.: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. (2004) 50:598-606.
5. GOSSEC L, VAN DER HEIJDE D, MELIAN A et al.: The Efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann. Rheum. Dis. (2005) In press.
6. STEINBACH G, LYNCH PM, PHILLIPS RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. (2000) 342:1946-1952.
7. ASANO TK, MCLEOD RS: Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst. Rev. (2004):CD004079.
8. PATRONO C, COLLER B, DALEN JE et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest (2001) 119:39S-63S.
9. NO AUTHORS LISTED: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71-86.
10. SANMUGANATHAN PS, GHAHRAMANI P, JACKSON PR, WALLIS EJ, RAMSAY LE: Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart (2001) 85:265-271.
11. HAYDEN M, PIGNONE M, PHILLIPS C, MULROW C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. (2002) 136:161-172.
12. MILLER MG, LUCAS BD, PAPADEMETRIOU V, ELHABYAN AK: Aspirin under fire: aspirin use in the primary prevention of coronary heart disease. Pharmacotherapy (2005) 25:847-861.
13. CHIOLÉRO A, MAILLARD M, BURNIER M: Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert Opin. Drug Saf. (2002) 1:45-52.
14. FINCKH A, ARONSON MD: Cardiovascular risks of cyclooxygenase-2 inhibitors: where we stand now. Ann. Intern. Med. (2005) 142:212-214.
15. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343:1520-1528.
16. BRESALIER RS, SANDLER RS, QUAN H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. (2005) 352:1092-1102.
17. SOLOMON SD, MCMURRAY JJ, PFEFFER MA et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. (2005) 352:1071-1080.
18. NUSSMEIER NA, WHELTON AA, BROWN MT et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. (2005) 352:1081-1091.
19. GARCIA RODRIGUEZ LA, VARAS-LORENZO C, MAGUIRE A, GONZALEZ-PEREZ A: Nonsteroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation (2004) 109:3000-3006.
20. HIPPISLEY-COX J, COUPLAND C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or traditional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br. Med. J. (2005) 330:1366-1372.
21. JOHNSEN SP, LARSSON H, TARONE RE et al.: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med. (2005) 165:978-984.
22. KIMMEL SE, BERLIN JA, REILLY M et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann. Intern. Med. (2005) 142:157-164.
23. JUNI P, NARTEY L, REICHENBACH S et al.: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 364:2021-2029.
24. BURNIER M: The safety of rofecoxib. Expert. Opin. Drug Saf. (2005) 4:491-499.
25. WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. (1999) 340:1888-1899.
26. KONSTAM MA, WEIR MR, REICIN A et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 104:2280-2288.
27. MUKHERJEE D, NISSEN SE, TOPOL EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 286:954-959.
28. KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384:644-648.
29. FELDMAN M, MCMAHON AT: Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. (2000) 132:134-143.
30. FITZGERALD GA: The choreography of cyclooxygenases in the kidney. J. Clin. Invest. (2002) 110:33-34.
31. FEENSTRA J, HEERDINK ER, GROBBEE DE, STRIKER BH. Association of non-steroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Arch. Int. Med. (2002) 162:265-270
32. KANNEL WB: Hypertension and the risk of cardiovascular disease. In: Hypertension: Pathophysiology, Diagnosis, and Management. Laragh JH, Brenner BM (Eds). Raven Press. New York. (1990):101-117.
33. BRATER DC, HARRIS RC, REDFERN JS, GERTZ BJ: Renal effects of COX-2 selective inhibitors. Am. J. Nephrol. (2001) 21:1-15.
34. MURATA T, USHIKUBI F, MATSUOKA T et al.: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 388:678-682.
35. KENNEDY CR, ZHANG Y, BRANDON S et al.: Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat. Med. (1999) 5:217-220.
36. CHENG Y, AUSTIN SC, ROCCA B et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 296:539-541.
37. EGAN KM, LAWSON JA, FRIES S et al.: COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 306:1954-1957.
38. VAN HECKEN A, SCHWARTZ JI, DEPRE M et al.: Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. (2000) 40:1109-1120.
39. CAPONE ML, TACCONELLI S, SCIULLI MG et al.: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation (2004) 109:1468-1471.
40. CATELLA-LAWSON F, REILLY MP, KAPOOR SC et al.: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. (2001) 345:1809-1817.
41. PATEL TN, GOLDBERG KC: Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch. Intern. Med. (2004) 164:852-856.
42. KONSTANTINOPOULOS PA, LEHMANN DF: The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J. Clin. Pharmacol. (2005) 45:742-750.
43. BOLTEN WW: The problem of the atherothrombotic potential of nonsteroidal anti-inflammatory drugs. Ann. Rheum. Dis. (2005) In press.
44. LEHMANN DF: Arthritis medications and cardiovascular events. JAMA (2005) 293:1976-1977.
45. HARRIS RC: Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. (2002) 89:10D-17D.
46. HARRIS RC, BREYER MD: Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal Physiol. (2001) 281:F1-F11.
47. KOMERS R, ANDERSON S, EPSTEIN M: Renal and cardiovascular effects of selective cyclooxygenase-2 inhibitors. Am. J. Kidney. Dis. (2001) 38:1145-1157.
48. STICHTENOTH DO, FROLICH JC: COX-2 and the kidneys. Curr. Pharm. Design (2000) 6:1737-1753.
49. FRISHMAN WH: Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am. J. Cardiol. (2002) 89:18D-25D.
50. SCHOOLEY RT, WAGLEY PF, LIETMAN PS: Edema associated with ibuprofen therapy. JAMA (1977) 237:1716-1717.
51. HEERDINK ER, LEUFKENS HG, HERINGS RM et al.: NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch. Intern. Med. (1998) 158:1108-1112.
52. PAGE J, HENRY D: Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch. Intern. Med. (2000) 160:777-784.
53. POPE JE, ANDERSON JJ, FELSON DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch. Intern. Med. (1993) 153:477-484.
54. FIERRO-CARRION GA, RAM CV: Nonsteroidal anti-inflammatory drugs (NSAIDs) and blood pressure. Am. J. Cardiol. (1997) 80:775-776.
55. JOHNSON AG, NGUYEN TV, DAY RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann. Intern. Med. (1994) 121:289-300.
56. SOWERS JR, WHITE WB, PITT B et al.: The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and Type 2 diabetes mellitus. Arch. Intern. Med. (2005) 165:161-168.
57. BARON JA, COLE BF, SANDLERS RS et al.: A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. (2003) 348:891-899
58. RIDKER PM, COOK NR, LEE IM et al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. (2005) 352:1293-1304.
59. RAY WA, STEIN CM, HALL K, DAUGHERTY JR, GRIFFIN MR: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 359:118-123.
60. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284:1247-1255.
61. SOLOMON DH, GLYNN RJ, LEVIN R, AVORN J: Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med. (2002) 162:1099-1104.
62. WATSON DJ, RHODES T, CAI B, GUESS HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. (2002) 162:1105-1110.
63. RAHME E, PILOTE L, LELORIER J: Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med. (2002) 162:1111-1115.
64. KIMMEL SE, BERLIN JA, REILLY M et al.: The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol. (2004) 43:985-990.
65. MAMDANI M, ROCHON P, JUURLINK DN et al.: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch. Intern. Med. (2003) 163:481-486.
66. GRAHAM DJ, CAMPEN D, HUI R et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet (2005) 365:475-481.
67. FARKOUH ME, KIRSHNER H, HARRINGTON RA et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 364:675-684.
68. ZHAO SZ, BURKE TA, WHELTON A, VON ALLMEN H, HENDERSON SC: Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Am. J. Manag. Care (2002) 8:S392-S400.
69. WONG D, WANG M, CHENG Y, FITZGERALD GA: Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr. Opin. Pharmacol. (2005) 5:204-210.
70. FISCHER LM, SCHLIENGER RG, MATTER CM, JICK H, MEIER CR: Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch. Intern. Med. (2004) 164:2472-2476.
71. FISCHER LM, SCHLIENGER RG, MATTER CM, JICK H, MEIER CR: Current use of nonsteroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy (2005) 25:503-510.